Welcome to our dedicated page for Scisparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on Scisparc stock.
SciSparc Ltd. (SPRC) is a clinical-stage pharmaceutical innovator developing cannabinoid-based therapies for neurological disorders while operating a consumer hemp products division. This page provides verified updates on both business segments, serving investors and stakeholders with essential news repository.
Access authoritative information on SPRC's clinical trial advancements, regulatory filings, and financial performance alongside developments in its hemp-derived product line. Content includes press releases detailing research milestones, partnership announcements, and strategic initiatives across therapeutic and consumer markets.
Key updates cover FDA communications, intellectual property developments, quarterly earnings disclosures, and operational expansions. All materials are curated to meet investor needs for decision-making clarity while maintaining compliance with financial reporting standards.
Bookmark this resource for streamlined access to SPRC's official announcements and analysis. Regularly updated content ensures stakeholders stay informed about the company's progress in pharmaceutical innovation and consumer market execution.
SciSparc (Nasdaq: SPRC) said NeuroThera Labs received an Israel patent for a proprietary combination of opioids and N-acylethanolamines designed to potentiate analgesia while reducing side effects.
The grant complements existing patents in Europe, Japan, Australia, and Canada. SciSparc holds a controlling interest of approximately 75% in NeuroThera. A pre-clinical study reported that combining palmitoylethanolamide (PEA) with oxycodone prolonged analgesic effect and reduced some oxycodone-related psychoactive adverse events. The release cites a $5.5–$5.7 billion 2024 global oxycodone market estimate and suggests an "opioid-sparing" effect that may lower required opioid doses.
SciSparc (Nasdaq: SPRC) announced on Dec. 2, 2025 that NeuroThera Labs (TSXV: NTLX), in which SciSparc holds a controlling interest of approximately 75%, signed a non-binding term sheet to acquire a majority stake in an Israeli quantum-enabled bio data analytics company.
Under the Term Sheet NeuroThera would acquire 55% equity of the Target Company in exchange for issuing common shares equal to 40% of NeuroThera’s share capital on a non-diluted basis. The Acquisition is subject to due diligence, definitive agreements, corporate and regulatory approvals, and customary closing conditions; there is no assurance the transaction will be completed.
SciSparc (Nasdaq: SPRC) signed a binding term sheet to acquire a treasury of patents, trademarks and IP rights for endoscopic systems and medical cameras from Xylo Technologies, principally the single-use MUSE™ transoral fundoplication system.
The consideration at closing will be ordinary shares representing 19.99% of SciSparc’s issued and outstanding share capital (or, at SciSparc’s option, pre-funded warrants). SciSparc plans to pursue exclusive distributor partnerships to commercialize MUSE across North America, Europe and Latin America. A May 2025 report valued the global GERD device market at $2.5B (2024), projected to $3.03B by 2030 (CAGR 3.24% 2025–2030).
SciSparc (Nasdaq: SPRC) signed a binding term sheet to acquire a treasury of patents, trademarks and know‑how for innovative endoscopic systems and medical cameras, principally the MUSE™ transoral fundoplication system from Xylo Technologies.
Under the term sheet SciSparc will issue upon closing ordinary shares representing 19.99% of issued and outstanding capital (or pre‑funded warrants in lieu). SciSparc plans to pursue exclusive regional distributor partnerships to commercialize MUSE™ across North America, Europe and Latin America. A May 2025 market report values the global GERD device market at $2.5B in 2024, projected to $3.03B by 2030 (CAGR 3.24% 2025–2030).
SciSparc (Nasdaq: SPRC) said on November 20, 2025 that NeuroThera Labs (TSXV: NTLX), in which SciSparc holds approximately 75% controlling interest, filed an Israeli patent application for a combination therapy of MEAI (5-methoxy-2-aminoindane) and N-acylethanolamines such as PEA targeting depression.
The filing expands a joint IP portfolio with Clearmind Medicine (Nasdaq: CMND); the collaboration has produced 13 patents filed to date covering MEAI and N-acylethanolamine combinations for disorders including alcohol use disorder, cocaine addiction, obesity and depression. The release cites preclinical data supporting MEAI's efficacy in reducing addictive behaviors while preserving normal reward pathways.
The announcement references World Health Organization data (August 2025) noting ~332 million people living with depression worldwide (≈5.7% of adults).
SciSparc (Nasdaq: SPRC) closed the acquisition and transfer transaction with Miza III Ventures (now Neurothera Labs Inc., TSXV: NTLX) effective October 22, 2025. SciSparc received 63,300,000 common shares, 4,000,000 warrants exercisable at CAD 0.25 until October 22, 2030, and up to 48,000,000 contingent rights tied to milestones. The Target Assets transferred had an aggregate value of approximately US$11.6 million while Neurothera enterprise value was ~US$3.3 million (including ~US$1.0M cash).
SciSparc holds a controlling stake of ~75%, potentially rising to ~84% if warrants and milestones are fully executed. SciSparc also committed CAD 1.0M via an unsecured convertible note maturing October 22, 2027. Transaction Securities are subject to TSXV escrow and final TSXV acceptance is pending.
SciSparc (Nasdaq: SPRC) announced on October 23, 2025 the closing of the sale of its majority-owned subsidiary MitoCareX to N2OFF (Nasdaq: NITO).
N2OFF purchased 6,622 MitoCareX shares from SciSparc for $700,000, exchanged remaining shares with the sellers for N2OFF common stock equaling 40% of N2OFF’s fully diluted capital, and reconstituted MitoCareX’s board. Sellers are entitled to 30% of N2OFF’s financing proceeds (capped at $1.6M) for five years and may receive up to 25% of N2OFF common stock as milestone-based issuances. MitoCareX focuses on mitochondrial SLC25 targets and uses the MITOLINE™ algorithm plus in vitro screening for anti-cancer small molecules.
SciSparc (Nasdaq: SPRC) announced on September 16, 2025 a board resolution to launch an initiative to develop quantum-powered 3D protein modeling for drug discovery, with a focus on neurological and rare diseases.
The program will form a dedicated research team, create a wholly owned Israeli subsidiary, collaborate with experts in quantum computing and structural biology, refine quantum algorithms for protein folding and protein-ligand interactions, and seek new intellectual property.
SciSparc (Nasdaq: SPRC) and Clearmind (Nasdaq: CMND) announced the publication of a U.S. patent application on Oct 20, 2025 covering a combination therapy of MEAI (5-methoxy-2-aminoindane) and N‑Acylethanolamines such as Palmitoylethanolamide (PEA) to address binge behavior disorders.
The patent application cites multiple binge behaviors including excessive alcohol use, eating disorders, tobacco use, compulsive shopping, and problematic sexual conduct. The filing describes a therapeutic rationale: MEAI to reduce impulsivity and reward-seeking and PEA for anti-inflammatory and neuroprotective support. The collaboration targets conditions including alcohol use disorder, cocaine addiction, obesity, and depression, and cites preclinical data supporting potential efficacy in reducing binge episodes while preserving natural reward pathways.
SciSparc (Nasdaq: SPRC) entered a definitive asset-and-share purchase agreement dated October 9, 2025, to transfer its advanced clinical-stage pharmaceutical portfolio and a ~51% stake in SciSparc Nutraceuticals into Miza III Ventures (TSXV: MIZA.P).
The agreement values the Target Assets at approximately US$11.6M and Miza enterprise value at approximately US$3.3M. SciSparc will receive 63,300,000 Miza common shares plus up to 48,000,000 contingent rights, yielding an expected post-close controlling interest of ~75%–84%. TSXV granted conditional approval; closing is anticipated on or about Oct 22, 2025. SciSparc may commit up to CAD1.0M via a 2-year convertible note at 7% and will receive 4,000,000 warrants exercisable at CAD0.25 for five years.
FAQ
What is the current stock price of Scisparc (SPRC)?
What is the market cap of Scisparc (SPRC)?
